Type 2 diabetes: pharmacologic glycemic management

Metformin remains initial pharmacotherapy for most adults who need glucose-lowering medication. Use immediate insulin, with or without metformin, when metabolic decompensation or severe symptomatic hyperglycemia makes slower escalation unsafe.

Combination therapy is often needed when A1C is more than 1.5 percentage points above the individualized target.

For the source-defined groups with high cardiovascular risk, heart failure or chronic kidney disease, prioritize agents with demonstrated benefit from the recommended GLP-1 receptor agonist or SGLT2 inhibitor categories, even when A1C alone would not require intensification.

Benefit is agent- and population-specific. Verify the exact evidence-backed agent, kidney-function limits, adverse effects and access criteria in the complete source and current product information.